Profil
Toru Seo is the founder of HISHOH Biopharma Co., Ltd.
where he holds the title of Advisor since 2021.
He is currently working as a Director at Cellusion Inc. Dr. Seo obtained a doctorate degree from Wake Forest University.
Aktive Positionen von Toru Seo
| Unternehmen | Position | Beginn |
|---|---|---|
Cellusion Inc.
 Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Cellusion Inc. is a Japanese company that focuses on regenerating corneal endothelium using IPS cells to treat bullous keratopathy. The company is based in Tokyo, Japan. The company was founded in 2015 by Shigeto Shimmura, Kazuo Tsubota, Shin Hatou. | Direktor/Vorstandsmitglied | - |
HISHOH Biopharma Co., Ltd.
 HISHOH Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services HISHOH Biopharma Co., Ltd. is a Japanese company that develops allergen immunotherapy. The company was founded in 2021 by Toru Seo and Naoki Sakurai. Naoki Sakurai has been the CEO since 2021. | Gründer | 12.04.2021 |
Ausbildung von Toru Seo
| Wake Forest University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cellusion Inc.
Cellusion Inc. Miscellaneous Commercial ServicesCommercial Services Cellusion Inc. is a Japanese company that focuses on regenerating corneal endothelium using IPS cells to treat bullous keratopathy. The company is based in Tokyo, Japan. The company was founded in 2015 by Shigeto Shimmura, Kazuo Tsubota, Shin Hatou. | Commercial Services |
HISHOH Biopharma Co., Ltd.
HISHOH Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services HISHOH Biopharma Co., Ltd. is a Japanese company that develops allergen immunotherapy. The company was founded in 2021 by Toru Seo and Naoki Sakurai. Naoki Sakurai has been the CEO since 2021. | Commercial Services |
